Literature DB >> 26968883

Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin.

Yu-Tzu Lin1, Jui-Chang Tsai2, Tatsuo Yamamoto3, Hsiao-Jan Chen1, Wei-Chun Hung4, Po-Ren Hsueh5, Lee-Jene Teng6.   

Abstract

OBJECTIVES: Small colony variants (SCVs) of Staphylococcus aureus are associated with persistent and drug-resistant infections. We demonstrated for the first time the emergence of SCVs in a patient with vancomycin-intermediate S. aureus (VISA) infection during long-term treatment with daptomycin.
METHODS: A 73-year-old man with septic arthritis was infected with VISA. The patient was treated with daptomycin; however, the patient remained infected with VISA, with continuous isolation of VISA from his blood during long-term treatment. Five VISA isolates were characterized by: PFGE; genotyping including staphylococcal cassette chromosome mec (SCCmec), spa and MLST; antimicrobial susceptibility testing; and scanning and transmission electron microscopy. WGS and fatty acid analysis were also performed.
RESULTS: The five VISA isolates were from a single clone of ST239/spa3(t037) and, of these, the first three were SCCmecIII positive and daptomycin susceptible, whereas the last two were SCCmecIII negative and daptomycin resistant and exhibited the characteristics of SCVs. The first and last isolates showed 13 remarkable genetic differences in SCCmec and the mprF, cls2, clpX and fabF genes. Of these, mutation of fabF (encoding the fatty acid synthase) seemed to be partially responsible for the slow growth and ultrastructural features, including an abnormal intercellular substance, and for the daptomycin resistance of SCVs.
CONCLUSIONS: For the first time, we identified SCVs of VISA in a patient with septic arthritis during long-term treatment with daptomycin. Daptomycin-resistant SCVs of VISA were evolved in a stepwise manner and the mutation of fabF is likely responsible for the physical and ultrastructural characteristics and daptomycin resistance.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26968883     DOI: 10.1093/jac/dkw060

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Clinical Relevance of Type II Fatty Acid Synthesis Bypass in Staphylococcus aureus.

Authors:  Karine Gloux; Mélanie Guillemet; Charles Soler; Claire Morvan; David Halpern; Christine Pourcel; Hoang Vu Thien; Gilles Lamberet; Alexandra Gruss
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Environmental fatty acids enable emergence of infectious Staphylococcus aureus resistant to FASII-targeted antimicrobials.

Authors:  Claire Morvan; David Halpern; Gérald Kénanian; Constantin Hays; Jamila Anba-Mondoloni; Sophie Brinster; Sean Kennedy; Patrick Trieu-Cuot; Claire Poyart; Gilles Lamberet; Karine Gloux; Alexandra Gruss
Journal:  Nat Commun       Date:  2016-10-05       Impact factor: 14.919

3.  Alternative Evolutionary Pathways for Drug-Resistant Small Colony Variant Mutants in Staphylococcus aureus.

Authors:  Sha Cao; Douglas L Huseby; Gerrit Brandis; Diarmaid Hughes
Journal:  MBio       Date:  2017-06-20       Impact factor: 7.867

4.  Molecular characterization of Streptococcus pneumoniae, particularly serotype19A/ST320, which emerged in Krasnoyarsk, Russia.

Authors:  Irina N Protasova; Tsai-Wen Wan; Natalya V Bakhareva; Wei-Chun Hung; Wataru Higuchi; Yasuhisa Iwao; Tatyana A Yelistratova; Natalya A Ilyenkova; Yelena S Sokolovskaya; Galina P Martynova; Ivan V Reva; Galina V Reva; Sergey V Sidorenko; Lee-Jene Teng; Olga V Peryanova; Alla B Salmina; Tatsuo Yamamoto
Journal:  Microbiol Immunol       Date:  2017-09       Impact factor: 1.955

5.  The Energy-Coupling Factor Transporter Module EcfAA'T, a Novel Candidate for the Genetic Basis of Fatty Acid-Auxotrophic Small-Colony Variants of Staphylococcus aureus.

Authors:  Nina Schleimer; Ursula Kaspar; Mike Drescher; Jochen Seggewiß; Christof von Eiff; Richard A Proctor; Georg Peters; André Kriegeskorte; Karsten Becker
Journal:  Front Microbiol       Date:  2018-08-14       Impact factor: 5.640

6.  Emergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis.

Authors:  Manuel Kussmann; Matthias Karer; Markus Obermueller; Katy Schmidt; Wolfgang Barousch; Doris Moser; Marion Nehr; Michael Ramharter; Wolfgang Poeppl; Athanasios Makristathis; Stefan Winkler; Florian Thalhammer; Heinz Burgmann; Heimo Lagler
Journal:  Emerg Microbes Infect       Date:  2018-12-05       Impact factor: 7.163

7.  Extracellular DNA released by glycine-auxotrophic Staphylococcus epidermidis small colony variant facilitates catheter-related infections.

Authors:  Junlan Liu; Zhen Shen; Jin Tang; Qian Huang; Ying Jian; Yao Liu; Yanan Wang; Xiaowei Ma; Qian Liu; Lei He; Min Li
Journal:  Commun Biol       Date:  2021-07-22

Review 8.  Virulence alterations in staphylococcus aureus upon treatment with the sub-inhibitory concentrations of antibiotics.

Authors:  Juan Chen; Huyue Zhou; Jingbin Huang; Rong Zhang; Xiancai Rao
Journal:  J Adv Res       Date:  2021-01-23       Impact factor: 10.479

9.  Genetic Basis of Emerging Vancomycin, Linezolid, and Daptomycin Heteroresistance in a Case of Persistent Enterococcus faecium Bacteremia.

Authors:  Kieran I Chacko; Mitchell J Sullivan; Colleen Beckford; Deena R Altman; Brianne Ciferri; Theodore R Pak; Robert Sebra; Andrew Kasarskis; Camille L Hamula; Harm van Bakel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

10.  Novel Daptomycin Tolerance and Resistance Mutations in Methicillin-Resistant Staphylococcus aureus from Adaptive Laboratory Evolution.

Authors:  Jordy Evan Sulaiman; Henry Lam
Journal:  mSphere       Date:  2021-09-29       Impact factor: 4.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.